ATG-102

ATG-102 is a bispecific T cell engager (TCE) developed by Antengene for the treatment of acute myeloid leukemia (AML), particularly targeting the monocytic M4/M5 subtypes. It is designed to simultaneously bind to two non-overlapping epitopes of leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4) on AML cells and a unique conformational epitope on CD3 on T cells. This dual binding induces potent T-cell dependent cellular cytotoxicity (TDCC) against LILRB4-positive AML cells, resulting in strong anti-tumor activity both in vitro and in vivo. The AnTenGager platform underlying ATG-102 incorporates steric hindrance-masking technology, which enables conditional activation of T cells only upon disease-associated antigen crosslinking, thereby reducing off-target effects and minimizing cytokine release syndrome risk[1][2][6].